21-May-2015 - Medicago, Inc.

Medicago to build $245M production facility in Quebec City

New complex will make vaccines and therapeutics using innovative plant technology

Medicago announced that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago's Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years.

Medicago chose Quebec City because of its qualified employees and the access to an experienced workforce, world-class research infrastructure, a dynamic business culture and support from the federal, provincial and municipal governments.

A new biotech complex for producing vaccines and treatments

Medicago's new complex will be built in Quebec City's Espace d'innovation D'Estimauville (Estimauville innovation park) and completed by 2019. It will regroup Medicago's head office, research and development activities, and commercial production plant.

Medicago's new 44 000 m2 facility will be located on a 90 000 m2 site. It will have the capacity to deliver up to 40 to 50 million doses of quadrivalent seasonal flu vaccines. In addition, work towards developing new products will take place over the upcoming years.

Facts, background information, dossiers
More about Medicago
  • News

    Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology

    Medicago Inc.  and Cellectis plant sciences, a subsidiary of Cellectis SA announced the signing of a research agreement under which Medicago and Cellectis will collaborate to improve therapeutic proteins expressed from tobacco leaves. "We look forward to working with Cellectis plant science ... more

    Medicago announces research collaboration for the development of a non-influenza vaccine candidate

    Medicago Inc. announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.Under the terms of the research collaboration, Medicago will apply its transient expression system to deve ... more

    Medicago announces an extension of its agreement with Genopole biopark

    Medicago Inc. announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense. This laborator ... more

  • Companies

    Medicago, Inc.

    Medicago is a publicly-traded biotechnology company focused on the development, production and commercialization of protein-based vaccines and biopharmaceuticals using a proprietary manufacturing system developed from its expertise in the genetic engineering of plants. more

    Medicago AB

    To be a trusted partner in the development and manufacture of critical bioreagents. To be committed to innovative solutions through excellence in research and development. To deliver highest level of quality products and world class services to our customers. To focus on broadering our rang ... more